The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Mingzhao Xing

Laboratory for Cellular and Molecular Thyroid Research

Johns Hopkins University School of Medicine

Baltimore

MD 21287

USA

[email]@jhmi.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Laboratory for Cellular and Molecular Thyroid Research, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA. 2013
  • Division of Endocrinology and Metabolism, the Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 333. 2004 - 2012

References

  1. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. Xing, M., Alzahrani, A.S., Carson, K.A., Viola, D., Elisei, R., Bendlova, B., Yip, L., Mian, C., Vianello, F., Tuttle, R.M., Robenshtok, E., Fagin, J.A., Puxeddu, E., Fugazzola, L., Czarniecka, A., Jarzab, B., O'Neill, C.J., Sywak, M.S., Lam, A.K., Riesco-Eizaguirre, G., Santisteban, P., Nakayama, H., Tufano, R.P., Pai, S.I., Zeiger, M.A., Westra, W.H., Clark, D.P., Clifton-Bligh, R., Sidransky, D., Ladenson, P.W., Sykorova, V. JAMA (2013) [Pubmed]
  2. The Akt Inhibitor MK2206 Synergizes, but Perifosine Antagonizes, the BRAFV600E Inhibitor PLX4032 and the MEK1/2 Inhibitor AZD6244 in the Inhibition of Thyroid Cancer Cells. Liu, R., Liu, D., Xing, M. J. Clin. Endocrinol. Metab. (2012) [Pubmed]
  3. Prognostic utility of BRAF mutation in papillary thyroid cancer. Xing, M. Mol. Cell. Endocrinol. (2010) [Pubmed]
  4. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Xing, M. Thyroid (2010) [Pubmed]
  5. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. Xing, M., Clark, D., Guan, H., Ji, M., Dackiw, A., Carson, K.A., Kim, M., Tufaro, A., Ladenson, P., Zeiger, M., Tufano, R. J. Clin. Oncol. (2009) [Pubmed]
  6. Recent advances in molecular biology of thyroid cancer and their clinical implications. Xing, M. Otolaryngol. Clin. North Am. (2008) [Pubmed]
  7. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Xing, M. Endocr. Rev. (2007) [Pubmed]
  8. Gene methylation in thyroid tumorigenesis. Xing, M. Endocrinology (2007) [Pubmed]
  9. BRAF mutation in thyroid cancer. Xing, M. Endocr. Relat. Cancer (2005) [Pubmed]
  10. The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer. Xing, M. Clin. Endocrinol. (Oxf) (2005) [Pubmed]
  11. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. Xing, M., Westra, W.H., Tufano, R.P., Cohen, Y., Rosenbaum, E., Rhoden, K.J., Carson, K.A., Vasko, V., Larin, A., Tallini, G., Tolaney, S., Holt, E.H., Hui, P., Umbricht, C.B., Basaria, S., Ewertz, M., Tufaro, A.P., Califano, J.A., Ringel, M.D., Zeiger, M.A., Sidransky, D., Ladenson, P.W. J. Clin. Endocrinol. Metab. (2005) [Pubmed]
  12. BRAF T1796A transversion mutation in various thyroid neoplasms. Xing, M., Vasko, V., Tallini, G., Larin, A., Wu, G., Udelsman, R., Ringel, M.D., Ladenson, P.W., Sidransky, D. J. Clin. Endocrinol. Metab. (2004) [Pubmed]
  13. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. Xing, M., Tufano, R.P., Tufaro, A.P., Basaria, S., Ewertz, M., Rosenbaum, E., Byrne, P.J., Wang, J., Sidransky, D., Ladenson, P.W. J. Clin. Endocrinol. Metab. (2004) [Pubmed]
 
WikiGenes - Universities